Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology. Takeda will pay ...
BridGene Biosciences Inc. has entered a strategic collaboration and licensing agreement with Takeda through which it will use ...
The current approval of Takeda’s Takhzyro pre-filled pen is an addition to the existing 150 mg and 300 mg pre-filled syringes ...
BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket ...
Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well ...
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has appointed Timothy P. Walbert, former chairman, president and chief executive officer of Horizon Therapeutics, to the ...